Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:O76050 (
neu
)
3,969
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of all-trans retinoic acid (ATRA) and epidermal growth factor (EGF) on the expression of
nm23-H1
, a metastasis suppressor gene, were studied in a human 7721 hepatocarcinoma cell line. It was discovered that the expression of
nm23-H1
mRNA was up-regulated by ATRA. This was compatible with the observation that the metastasis-associated phenotypes, such as chemotaxic cell migration and invasion, were both reduced in the ATRA-treated and
nm23-H1
-cDNA-transferred 7721 cells. However, ability of cells to adhere to fibronectin and laminin was not altered identically in the ATRA-treated and
nm23-H1
-cDNA-transfected 7721 cells. In contrast, the expression of
nm23-H1
mRNA in 7721 cells was down-regulated both by the treatment with EGF and by the transfection of c-erbB-2/
neu
cDNA, which codes a protein homologous to the EGF receptor. EGF is a compound with biological effects opposite to those of ATRA, and c-erbB-2/
neu
is known to be a metastasis-promoting gene. These results reveal that the metastasis-preventing effect of ATRA may partly result from the up-regulation of
nm23-H1
, and the metastasis-promoting effects of EGF and c-erbB-2/
neu
were probably mediated in part by the down-regulation of
nm23-H1
.
...
PMID:Effects of all-trans retinoic acid and epidermal growth factor on the expression of nm23-H1 in human hepatocarcinoma cells. 1066 47
